Over 250 Cancer Monoclonal Antibody Partnering Deals Covered in Report: 2010 – 2015

1
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.

• Published September 2015
• No. of Pages 659
• Single User PDF US 1995

2
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• The Global Cancer Monoclonal Antibody Partnering
  2010-2015 Deal trends, players, financials and
  forecasts report provides an understanding and
  access to the cancer monoclonal antibody
  partnering deals and agreements entered into by
  the worlds leading healthcare companies.
• Trends in cancer monoclonal antibody
  partnering deals
• Disclosed headlines, upfronts, milestones and
  royalties by stage of development
• Cancer monoclonal antibody partnering
  contract documents
• Top cancer monoclonal antibody deals by value
• The Global Cancer Monoclonal Antibody Partnering
  2010-2015 Deal trends, players, financials and
  forecasts report provides an understanding and
  access to the cancer monoclonal antibody
  partnering deals and agreements entered into by
  the worlds leading healthcare companies.
• The report provides an understanding and analysis
  of how and why companies enter cancer monoclonal
  antibody partnering deals. The majority of deals
  are discovery stage whereby the licensee obtains
  a right or an option right to license the
  licensors monoclonal antibody technology. These
  deals tend to be multicomponent, starting with
  collaborative RD, and commercialization of
  outcomes.
• Complete Report available at http//www.reportsnre
  ports.com/reports/370259-global-cancer-monoclonal-
  antibody-partnering-2010-2015-deal-trends-players-
  financials-and-forecasts.html.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
3
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• Understanding the flexibility of a prospective
  partner's negotiated deals terms provides
  critical insight into the negotiation process in
  terms of what you can expect to achieve during
  the negotiation of terms. Whilst many smaller
  companies will be seeking details of the payments
  clauses, the devil is in the detail in terms of
  how payments are triggered - contract documents
  provide this insight where press releases do not.
• This report contains over 250 links to online
  copies of actual cancer monoclonal antibody deals
  and where available, contract documents as
  submitted to the Securities Exchange Commission
  by companies and their partners. Contract
  documents provide the answers to numerous
  questions about a prospective partner's
  flexibility on a wide range of important issues,
  many of which will have a significant impact on
  each party's ability to derive value from the
  deal.
• The initial chapters of the report provide an
  orientation of cancer monoclonal dealmaking and
  its associated business and partnering
  activities. This chapter provides an overall
  introduction to the report and what you will
  learn from it, whilst chapter 2 provides an
  overview of the trends in cancer monoclonal
  antibody deal making since 2010, categorizing by
  deal type, industry sector, stage of development
  and technology type.
• Purchase a Copy of this report _at_
  http//www.reportsnreports.com/purchase.aspx?name
  370259.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
4
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• A popular chapter with readers chapter 3 covers
  the average financial deal terms for deals signed
  in the cancer monoclonal antibody field with a
  stage of development announced. Deals are listed
  and sectioned by average headlines, upfront
  payments, milestone payments and royalty rates.
  The median values of these deals are then
  presented by stage of development at signing.
• Numerous tables and figures are weaved within the
  report to support the findings and illustrate the
  trends and activities in cancer monoclonal
  antibody partnering and dealmaking since 2010.
• Chapter 4 covers the leading cancer monoclonal
  antibody deals that have been announced over the
  past five years. Deals are listed by headline
  value. Where the deal has an agreement contract
  published at the SEC a link provides online
  access to the contract. Full deal contract
  documents where available for each deal are
  indicated by a yes/no symbol. Within this chapter
  the most active cancer monoclonal antibody deal
  makers are also listed as well as the deal making
  activities and the number of deals entered into
  by the big pharma and biotech companies.

Inquiry Before Buying on this Report _at_
http//www.reportsnreports.com/contacts/inquirybef
orebuy.aspx?name370259.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• Chapter 5 acts as a contracts reference directory
  chapter providing a full comprehensive and
  detailed list of the Cancer monoclonal antibody
  partnering deals signed and announced since
  January 2010. This chapter is organized by
  company A-Z, stage of development at signing,
  deal type (collaborative RD, co-promotion,
  licensing etc), and therapy focus. In order for
  readers to view full details of each agreement
  the report is formatted so that each deal title
  links via Weblink to an online version of the
  actual deal at Current Agreements
  (www.currentagreements.com) deals and alliances
  database.
• Chapter 6 brings the report to a conclusion by
  looking ahead to the future of cancer monoclonal
  antibody partnering. Newly introduced to provide
  readers with potential prospects and partnering
  insights this chapter selects emerging companies
  to watch in 2015 and details their recent deal
  making and financial activities. These companies
  could be potential targets for those who want to
  invest or partner in the coming months.
• In conclusion, this report gives prospective
  dealmakers a thorough overview of all the deals
  announced in the cancer monoclonal antibody field
  preparing them with everything they need to know
  about partnering in the research, development and
  commercialization of cancer monoclonal antibody
  technologies and products.

Inquire for Discount at www.reportsnreports.com/co
ntacts/Discount.aspx?name370259.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
6
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• In conclusion, this report gives prospective
  dealmakers a thorough overview of all the deals
  announced in the cancer monoclonal antibody field
  preparing them with everything they need to know
  about partnering in the research, development and
  commercialization of cancer monoclonal antibody
  technologies and products.
• Report scope
• Global Cancer Monoclonal Antibody Partnering
  2010-2015 Deal trends, players, financials and
  forecasts is intended to provide the reader with
  an in-depth understanding and access to cancer
  monoclonal antibody trends and structure of deals
  entered into by leading companies worldwide.
• Global Cancer Monoclonal Antibody Partnering
  2010-2015 Deal trends, players, financials and
  forecasts includes
• Trends in cancer monoclonal antibody
  dealmaking in the biopharma industry since 2009
• Analysis of cancer monoclonal antibody deal
  structure
• Access to headline, upfront, milestone and
  royalty data
• Access to over 250 cancer monoclonal antibody
  deal records
• The leading cancer monoclonal antibody deals
  by value since 2009

Inquiry Before Buying on this Report _at_
http//www.reportsnreports.com/contacts/inquirybef
orebuy.aspx?name370259.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
7
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• The Global Cancer Monoclonal Antibody Partnering
  2010-2015 Deal trends, players, financials and
  forecasts report provides comprehensive access to
  available deals and contract documents for over
  250 cancer monoclonal antibody deals. Analyzing
  actual contract agreements allows assessment of
  the following
• What are the precise rights granted or
  optioned?
• What is actually granted by the agreement to
  the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How aresales and payments audited?
• What is the deal term?
• How are the key terms of the agreement
  defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply,
  and manufacture?
• How is confidentiality and publication
  managed?

Purchase a Copy of this report _at_
http//www.reportsnreports.com/purchase.aspx?name
370259.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
8
Global Cancer Monoclonal Antibody Partnering
2010-2015 Deal Trends, players, financials and
forecasts

• Global Cancer Monoclonal Antibody Partnering
  2010-2015 Deal trends, players, financials and
  forecasts provides the reader with the following
  key benefits
• In-depth understanding of cancer monoclonal
  antibody deal trends since 2010
• Access to headline, upfront, milestone and
  royalty data
• Acces to the structure of cancer monoclonal
  antibody agreements with numerous real life case
  studies
• Comprehensive access to over 250 actual cancer
  monoclonal antibody deals entered into by the
  world's biopharma companies
• Insight into the terms included in a cancer
  monoclonal antibody agreement, together with real
  world clause examples
• Understand the key deal terms companies have
  agreed in previous deals
• Undertake due diligence to assess suitability of
  your proposed deal terms for partner companies

Complete Report available at http//www.reportsnre
ports.com/reports/370259-global-cancer-monoclonal-
antibody-partnering-2010-2015-deal-trends-players-
financials-and-forecasts.html.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.